Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Liminal Biosciences Inc.
Headquarters: Laval, QC, Canada
Website: https://liminalbiosciences.co...
Year Founded: 1994
Status: Public
Industry Sector: HealthTechnology
CEO: Bruce Philip Pritchard
Number Of Employees: 43
Enterprise Value: $-16,228,100
PE Ratio: 27.62
Exchange/Ticker 1: NASDAQ:LMNL
Exchange/Ticker 2: N/A
Latest Market Cap: $19,816,000
BioCentury | Jan 6, 2022
Management Tracks
COO Haviland to become new Blueprint CEO; Albers sliding to executive chair
Plus Galbraith succeeding Tehrani at Zymeworks and updates from Catalent, Bicycle, ADARx and more
BioCentury | Aug 11, 2021
Finance
Aug. 10 Quick Takes: SPAC to deliver GreenLight to NASDAQ with $282M
Eliem prices $80M IPO, plus updates from Moderna, Arcturus, Liminal, Sydnexis and LQT
BioCentury | Jun 17, 2021
Management Tracks
Syncona expands C-suite; plus Myriad, Aulos, Cytovia, Elevation and more
Syncona Ltd. (LSE:SYNC) hired Rolf Soderstrom as CFO, Markus John as CMO and head of R&D and Fiona Langton-Smith as chief human resources officer. Soderstrom, who previously served as CFO of BTG
BioCentury | Jun 5, 2021
Regulation
June 4 Quick Takes: FDA approves Novo’s semaglutide for chronic weight management; plus Liminal, Regeneron, Rigel, Myra and more
In FDA’s first approval of a new therapy for chronic weight management since 2014, the agency approved GLP-1 analog Wegovy semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO). The
BioCentury | Jun 2, 2021
Regulation
June 2021 PDUFA dates: Data Byte
At least 16 compounds have PDUFA dates in the month of June, over half of which have been granted priority review by FDA, according to BioCentury’s BCIQ database. FDA approved the first of the
BioCentury | Apr 8, 2021
Management Tracks
Fineberg to lead SVB Leerink’s structured finance group; plus Gimv, Syncona, Tessera, NKGen and more
SVB Leerink hired Andrew Fineberg as managing director to lead the firm’s new structured finance group. Fineberg joins from MTS Health Partners, where he served as partner and head of royalty
BioCentury | Jan 10, 2020
Emerging Company Profile
NorthSea: Engineering fatty acids for NASH
NorthSea’s structurally engineered fatty acids hit on key NASH mechanisms
BioCentury | Mar 2, 2018
Clinical News
Prometic discontinues Phase II of PBI-4050 to treat cystic fibrosis related diabetes
BioCentury | Nov 30, 2017
Clinical News
Prometic reports Phase II data for PBI-4050 in Alstrom syndrome
Items per page:
1 - 10 of 20